Truvian closes $105M oversubscribed Series C

Truvian Sciences announced today that it closed an oversubscribed Series C financing round worth more than $105 million.

TYH Ventures, Glen Tullman of 7wireVentures and Wittington Ventures led the funding round, the proceeds from which are earmarked for the development of Truvian’s automated benchtop blood testing system, according to a news release.

The benchtop system is designed to combine chemistries, immunoassays and hematology assays in one device, with the combination of such testing modalities allowing clinics to perform all standard blood tests during a routine check-up on-site, saving cost and time.

San Diego-based Truvian said the funding will pave the way to submit the device for FDA clearance and to scale its team in preparation for broad commercialization. The company has raised more than $150 million to date.

“The global pandemic has further demonstrated that consumers want more control over their per…

Read more
  • 0

FDA issues EUA for Truvian COVID-19 test

Truvian Sciences announced that it received FDA emergency use authorization (EUA) for its Easy Check COVID-19 IgM/IgG antibody test.

San Diego-based Truvian’s test is now being produced at a mass scale at a U.S.-based manufacturing facility and will be made available to healthcare practitioners immediately, according to a news release.

The test has undergone validation at the University of California San Diego and University of Chicago, recording 98.44% sensitivity and 98.9% specificity and no cross-reactivity with HIV, influenza A and B and several coronavirus strains. Further validation at the Frederick National Laboratory for Cancer Research found a sensitivity of 100% and specificity of 97.5%.

“Truvian’s Easy Check performed exceptionally well, with a robust sample set, in both our own studies, as well as the studies conducted by independent laboratories,” Truvian Sciences President & CEO Jeff Hawkins said in the release.…

Read more
  • 0